Table 1.
Baseline characteristics of the included trials.
| Study | Year | Patients (n) | Mean age (years) | Male,% | Mean Lad (mm) | Mean LVEF (%) | Hypertension (%) | DM(%) | CAD(%) | Follow-up (months) | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| PAF n (%) | PerAF n (%) | ||||||||||
| Andrade | 2019 | 327 (94.5) | 19 (5.5) | 59 | 67 | 37.8 | 59.2 | 34.7 | NR | 7.2 | 12 |
| You | 2019 | 140 (100) | 0 (0) | 58.6 | 56.4 | NR | NR | 56.5 | 17.9 | NR | 12 |
| Giannopoulos | 2019 | 120 (100) | 0 (0) | 60 | NR | 40.5 | 60 | 49.2 | 12.5 | 6.7 | 6 |
| Buist | 2018 | 229 (85.1) | 40 (14.9) | 58.9 | 71 | NR | NR | 40.8 | 23 | NR | 12 |
| Watanabe | 2018 | 52 (100) | 0 (0) | 65 | 72 | 40.5 | 60.5 | 60 | 16 | NR | 12 |
| Gunawardene | 2018 | 60 (100) | 0 (0) | 59.7 | 70 | NR | 59.5 | 55 | NR | NR | 12 |
PAF = paroxysmal atrial fibrillation, PerAF = persistent atrial fibrillation, LAd = left atrial diameter, LVEF = left ventricular ejection fraction, DM = diabetes mellitus, CAD = coronary artery disease, NR = not reported.